Daiwa Securities Group
VIR icon

Daiwa Securities Group’s Vir Biotechnology VIR Stock Holding History

Daiwa Securities Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,763
Closed -$65K – 1443
2025
Q4 		$65K Sell
10,763
-518
-5% -$3.08K ﹤0.01% 1082
2025
Q3 		$64K Sell
11,281
-1,027
-8% -$5.25K ﹤0.01% 1072
2025
Q2 		$62K Buy
12,308
+11,773
+2,201% +$63.1K ﹤0.01% 1047
2025
Q1 		$3K Hold
535
– – ﹤0.01% 1170
2024
Q4 		$4K Hold
535
– – ﹤0.01% 1181
2024
Q3 		$4K Hold
535
– – ﹤0.01% 1190
2024
Q2 		$5K Hold
535
– – ﹤0.01% 1202
2024
Q1 		$5K Hold
535
– – ﹤0.01% 1214
2023
Q4 		$5K Hold
535
– – ﹤0.01% 1209
2023
Q3 		$5K Hold
535
– – ﹤0.01% 1165
2023
Q2 		$13K Hold
535
– – ﹤0.01% 1129
2023
Q1 		$12K Hold
535
– – ﹤0.01% 1101
2022
Q4 		$14K Buy
535
+42
+9% +$1.03K ﹤0.01% 1096
2022
Q3 		$10K Hold
493
– – ﹤0.01% 1127
2022
Q2 		$13K Buy
493
+111
+29% +$2.59K ﹤0.01% 1134
2022
Q1 		$10K Hold
382
– – ﹤0.01% 1141
2021
Q4 		$16K Sell
382
-65
-15% -$2.55K ﹤0.01% 1132
2021
Q3 		$19K Buy
447
+194
+77% +$8.4K ﹤0.01% 1109
2021
Q2 		$12K Hold
253
– – ﹤0.01% 1039
2021
Q1 		$13K Buy
253
+13
+5% +$701 ﹤0.01% 1033
2020
Q4 		$6K Buy
+240
New +$7.8K ﹤0.01% 1052

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Daiwa Securities Group's VIR Position: Q1 2026 in Review

Daiwa Securities Group sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 10,763 shares — an estimated $65K sold.

Daiwa Securities Group first reported a position in VIR in Q4 2020 and held it in 21 quarters. The position peaked at $65K in Q4 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Daiwa Securities Group reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 10,763 Vir Biotechnology shares in Q1 2026, an estimated $65K.
  • Daiwa Securities Group first reported a position in Vir Biotechnology in Q4 2020 and held it in 21 quarters.
  • Daiwa Securities Group's Vir Biotechnology position peaked at $65K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.